Belarus Pharmaceuticals and Healthcare Report Q1 2015

Business Monitor International
December 17, 2014
87 Pages - SKU: BMI5416294
Countries covered: Belarus

Belarus Pharmaceuticals and Healthcare Report Q1 2015

BMI View: The Belarusian market will suffer from the impact of depreciation and economic instability asthe country's economy becomes ever more reliant on Russian loans to function. Furthermore, wage growthmandated by the government will become unsustainable, threatening to dampen internal consumption.

Belarus will present little reward for high risk for most pharmaceutical companies in the region.

Headline Expenditure Projections

Pharmaceuticals: BYR8,927bn in 2013 (USD1.00bn) to BYR11,490bn (USD1.09bn) in 2014; +28.7% inlocal currency terms and +9.2% in US dollar terms.

Healthcare: BYR29,768bn (USD3.34bn) in 2013 to BYR37,249bn (USD3.55bn) in 2014; +25.1% in localcurrency terms and +6.1% in US dollar terms.



More Prescription Drugs reports by Business Monitor International

Taiwan Pharmaceuticals and Healthcare Report Q1 2015 by Business Monitor International
Taiwan Pharmaceuticals and Healthcare Report Q1 2015BMI View: Taiwan is one of the most attractive and stable prospects in the region for pharmaceutical andhealthcare investment, ...
Switzerland Pharmaceuticals and Healthcare Report Q1 2015 by Business Monitor International
Switzerland Pharmaceuticals and Healthcare Report Q1 2015BMI View: The Swiss government will need to develop policies to maintain the country's long-termattractiveness as a site for ...
Sudan Pharmaceuticals and Healthcare Report Q1 2015 by Business Monitor International
Sudan Pharmaceuticals and Healthcare Report Q1 2015BMI View: The already depreciating Sudanese pound will come under further strain should oil pricescontinue their decline as oil ...
Saudi Arabia Pharmaceuticals and Healthcare Report Q1 2015 by Business Monitor International
Saudi Arabia Pharmaceuticals and Healthcare Report Q1 2015BMI View: We expect heavy investment into Saudi Arabia's healthcare sector to continue, particularly asthe government sees the ...
See all reports like this >>

More Belarus Prescription Drugs reports

Pharmaceuticals and Healthcare Report - Belarus Q4 2014 by Business Monitor International
Pharmaceuticals and Healthcare Report - Belarus Q4 2014BMI View: The Belarusian market will suffer from the impact of prolonged rouble depreciation andeconomic instability. ...
Belarus Pharmaceuticals and Healthcare Report Q2 2014 by Business Monitor International
Belarus Pharmaceuticals and Healthcare Report Q2 2014BMI View: Pharmaceutical sales in Belarus are poised to recover as the fallout from the breaking of thepotash joint ...
Belarus Pharmaceuticals and Helathcare Report Q3 2012 by Business Monitor International
BMI View: The short-term outlook for the Belarusian pharmaceutical market is deeply uncertain due toexchange-rate volatility and the economy’s lack of capacity for progress without ...
See all reports like this >>

 

SELECT A LICENSE

    Report with 3 quarterly updates  USD 1,295  
    Report with 3 quarterly updates
3 User License
  USD 1,945  
    Report with 3 quarterly updates
5 User License
  USD 2,500  
    Report with 3 quarterly updates
Departmental/Site License
  USD 2,995  
    Global Site License Fulfilled by Publisher  USD 6,995  
 
US: 800.298.5699
Int'l: +1.240.747.3093
 

Share this report


    Other tasks

     
     
    Join Alert Me now!
    Receive bi-weekly email alerts on new market research

    Sign up today!